Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance
Citations Over TimeTop 10% of 2015 papers
Abstract
Colorectal cancer (CRC) is characterized by recurrent mutations deregulating key cell signaling cascades and providing the cancer cells with novel functional traits. Among the most frequent mutations in CRC are gain-of-function missense mutations in KRAS and BRAF. Oncogenic activation of KRAS and BRAF is mutually exclusive and occurs in approximately 40% and 10% of all CRCs, respectively. Here we summarize genetic alterations currently described in the literature and databases, indicating overlapping but also specific co-occurrences with either mutated BRAF or KRAS. We describe common and potentially specific biological functions of KRAS and BRAF oncoproteins in the intestinal epithelial cells and during initiation and progression of CRC. We discuss signal transduction networks, highlighting individual functions of oncogenic KRAS and BRAF in terms of feedback loops and their impact on treatment outcome. Finally, we give an update on current strategies of targeted therapeutic intervention in oncogenic RAS-RAF signaling networks for the treatment of metastatic CRC and outline future directions.
Related Papers
- → Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer(2012)248 cited
- → Therapeutic Targets of KRAS in Colorectal Cancer(2021)33 cited
- → Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.(2020)3 cited
- → Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer(2020)2 cited
- → 127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinoma(2022)